IDEAYA Biosciences (IDYA) Cash & Current Investments (2018 - 2026)

IDEAYA Biosciences has reported Cash & Current Investments for 9 years, with the latest figure at $671.2 million in Q1 2026.

• Quarterly Cash & Current Investments fell 35.58% year-over-year to $671.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $671.2 million (down 35.58% YoY) and the FY2025 annual result came in at $639.4 million, down 5.46% from the prior year.
• Cash & Current Investments rose to $671.2 million in Q1 2026 per IDYA's latest filing, from $639.4 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $1.0 billion in Q1 2025 and troughed at $252.6 million in Q1 2022.
• A 5-year average of $582.7 million and a median of $639.4 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2026: Cash & Current Investments soared 105.84% in 2024, then slumped 35.58% in 2026.
• Over 5 years, Cash & Current Investments stood at $364.8 million in 2022, then surged by 43.93% to $525.1 million in 2023, then rose by 28.79% to $676.3 million in 2024, then declined by 5.46% to $639.4 million in 2025, then rose by 4.98% to $671.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $671.2 million, $639.4 million, and $786.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.